IP Library Granted Patent US 10,765,665
Granted Patent B2
US 10,765,665 · App. 15/241,312 · Granted Sep 8, 2020

Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases

Inventor: Jeffrey M. Melin (Meadowbrook, PA)
A61K31/436A61K9/0014A61K9/0087A61K9/06A61K31/155A61K31/519A61K47/10A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,765,665
App. No.
15/241,312
Granted
Sep 8, 2020
Kind
B2
Abstract

A formulation, especially one that is topically administered, comprising a combination of rapamcycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat any disease associated with inflammation and/or any inflammatory skin disease.

Claims (14)

1. A method for treating symptoms of inflammatory arthritis in a subject, wherein the method comprises locally administering an effective amount of a topical formulation directly over an inflamed joint affected by inflammatory arthritis, the topical formulation comprising a combination of rapamycin and metformin, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1, and wherein metformin acts as an adjuvant to enhance efficacy of rapamycin in the topical formulation.

2. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 15:1 to about 3:1.

3. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 10:1 to about 4:1.

4. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is about 5:1 to about 3:1.

5. The method of claim 1 , wherein the molar ratio of rapamycin to metformin is about 5:1 to about 4:1.

6. The method of claim 1 , wherein the inflammatory arthritis is osteoarthritis.

7. A method for treating the symptoms of inflammatory arthritis in a subject comprising administering an effective amount of a formulation comprising a combination of rapamycin and metformin to a subject with inflammatory arthritis, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1.

8. The method of claim 7 , wherein the molar ratio of rapamycin to metformin is in the range of about 15:1 to about 3:1.

9. The method of claim 7 , wherein the molar ratio of rapamycin to metformin is in the range of about 10:1 to about 4:1.

10. The method of claim 7 , wherein the molar ratio of rapamycin to metformin is about 5:1 to about 3:1.

11. The method of claim 7 , wherein the ratio of rapamycin to metformin is about 5:1 to about 4:1.

12. The method of claim 7 , wherein the inflammatory arthritis is osteoarthritis.

13. The method of claim 7 , wherein the formulation is administered orally.

14. The method of claim 7 , wherein the formulation is administered topically.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: MELIN, JEFFREY M.
To: JMM LICENSING LLC
Reel/Frame 057426/0207 →
Continuity (3)
Provisional Application 62259384 · Nov 24, 2015
Provisional Application 62318302 · Apr 5, 2016
Related Publication 20170143682A1 · May 25, 2017
Cited By (1)
US 12,409,170